FGF23 signaling impairs neutrophil recruitment and host defense during CKD

Journal of Clinical Investigation

Volumn 126, Issue 3, 2016, Pages 962-974

  Rossaint, Jan ^a,b   Oehmichen, Jessica ^a,b   Van Aken, Hugo ^a   Reuter, Stefan ^a   Pavenstädt, Hermann J ^a   Meersch, Melanie ^a   Unruh, Mark ^c   Zarbock, Alexander ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 2; RAP1 PROTEIN; SELECTIN; FGFR2 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HOST RESISTANCE; HUMAN; INTRAVITAL MICROSCOPY; LEUKOCYTE ACTIVATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; ANIMAL; BACTERIAL PNEUMONIA; C57BL MOUSE; CASE CONTROL STUDY; CELLULAR IMMUNITY; CHRONIC KIDNEY FAILURE; HEK293 CELL LINE; HL-60 CELL LINE; IMMUNOLOGY; LEUKOCYTE ROLLING; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AGED; ANIMALS; ANTIGENS, CD18; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HEK293 CELLS; HL-60 CELLS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTE ROLLING; MALE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NEUTROPHILS; PNEUMONIA, BACTERIAL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84959894121     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83470     Document Type: Article

References (58)

1. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-180.
2. Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis. 2011;216(2):446-451.
3. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469-473.
4. Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med. 2011;17(11):1381-1390.
5. Ley K. Arrest chemokines. Microcirculation. 2003;10(3-4):289-295.
6. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-689.
7. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619-647.
8. Zarbock A, Deem TL, Burcin TL, Ley K. Galphai2 is required for chemokine-induced neutrophil arrest. Blood. 2007;110(10):3773-3779.
9. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139-149.
10. Shimada T, et al. Cloning and characterization of FGF23 as a causative factor of tumorinduced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500-6505.
11. Kurosu H, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120-6123.
12. Urakawa I, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770-774.
13. Isakova T, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378.
14. Shimada T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010;95(2):578-585.
15. Gutierrez OM, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
16. Isakova T, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432-2439.
17. Faul C, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408.
18. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27(1):227-237.
19. Haddad LE, Khzam LB, Hajjar F, Merhi Y, Sirois MG. Characterization of FGF receptor expression in human neutrophils and their contribution to chemotaxis. Am J Physiol Cell Physiol. 2011;301(5):C1036-C1045.
20. Hayakawa S, et al. Cardiac myocyte-derived follistatin-like 1 prevents renal injury in a subtotal nephrectomy model. J Am Soc Nephrol. 2015;26(3):636-646.
21. Leelahavanichkul A, et al. Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1. Kidney Int. 2011;80(11):1198-1211.
22. Ittner A, et al. Regulation of PTEN activity by p38PKD1 signaling in neutrophils confers inflammatory responses in the lung. J Exp Med. 2012;209(12):2229-2246.
23. Block H, et al. Crucial role of SLP-76 and ADAP for neutrophil recruitment in mouse kidney ischemia-reperfusion injury. J Exp Med. 2012;209(2):407-421.
24. Kuwano Y, Spelten O, Zhang H, Ley K, Zarbock A. Rolling on E-or P-selectin induces the extended but not high-affinity conformation of LFA-1 in neutrophils. Blood. 2010;116(4):617-624.
25. Herter JM, Rossaint J, Block H, Welch H, Zarbock A. Integrin activation by P-Rex1 is required for selectin-mediated slow leukocyte rolling and intravascular crawling. Blood. 2013;121(12):2301-2310.
26. Grabner A, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22(6):1020-1032.
27. Rossaint J, Vestweber D, Zarbock A. GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost. 2012;11(2):335-344.
28. Thompson S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26(10):2504-2511.
29. Anders HJ, Ninichuk V, Schlondorff D. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int. 2006;69(1):29-32.
30. AnDing K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant. 2003;18(10):2067-2073.
31. Rossaint J, et al. Acute loss of renal function attenuates slow leukocyte rolling and transmigration by interfering with intracellular signaling. Kidney Int. 2011;80(5):493-503.
32. Bacchetta J, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 2013;28(1):46-55.
33. Viaene L, Evenepoel P, Meijers B, Vanderschueren D, Overbergh L, Mathieu C. Uremia suppresses immune signal-induced CYP27B1 expression in human monocytes. Am J Nephrol. 2012;36(6):497-508.
34. Shalhoub V, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122(7):2543-2553.
35. Zarbock A, Kempf T, Wollert KC, Vestweber D. Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. J Mol Med. 2012;90(4):353-359.
36. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-1172.
37. Kempf T, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17(5):581-588.
38. Drechsler M, et al. Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ Res. 2015;116(5):827-835.
39. Eskan MA, et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol. 2012;13(5):465-473.
40. Kinashi T, Katagiri K. Regulation of lymphocyte adhesion and migration by the small GTPase Rap1 and its effector molecule, RAPL. Immunol Lett. 2004;93(1):1-5.
41. Kinashi T, et al. LAD-III, a leukocyte adhesion deficiency syndrome associated with defective Rap1 activation and impaired stabilization of integrin bonds. Blood. 2004;103(3):1033-1036.
42. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4):F882-F889.
43. Weinman EJ, Steplock D, Shenolikar S, Biswas R. Fibroblast growth factor-23-mediated inhibition of renal phosphate transport in mice requires sodium-hydrogen exchanger regulatory factor-1 (NHERF-1) and synergizes with parathyroid hormone. J Biol Chem. 2011;286(43):37216-37221.
44. Mizuno R, et al. In vivo imaging reveals PKA regulation of ERK activity during neutrophil recruitment to inflamed intestines. J Exp Med. 2014;211(6):1123-1136.
45. Li J, Zhao L, He X, Zeng YJ, Dai SS. Sinomenine protects against lipopolysaccharide-induced acute lung injury in mice via adenosine A(2A) receptor signaling. PLoS One. 2013;8(3):e59257.
46. Reber LL, Daubeuf F, Nemska S, Frossard N. The AGC kinase inhibitor H89 attenuates airway inflammation in mouse models of asthma. PLoS One. 2012;7(11):e49512.
47. Yu HP, Hsieh PW, Chang YJ, Chung PJ, Kuo LM, Hwang TL. 2-(2-Fluorobenzamido)benzoate ethyl ester (EFB-1) inhibits superoxide production by human neutrophils and attenuates hemorrhagic shock-induced organ dysfunction in rats. Free Radic Biol Med. 2011;50(12):1737-1748.
48. Neel NF, et al. VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci. 2009;122(pt 11):1882-1894.
49. Isakova T, et al. Associations of FGF23 with change in bone mineral density and fracture risk in older individuals [published online ahead of print November 21, 2015]. J Bone Miner Res. doi:10.1002/jbmr.2750.
50. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737-747.
51. Mocsai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol. 2006;7(12):1326-1333.
52. Zarbock A, Abram CL, Hundt M, Altman A, Lowell CA, Ley K. PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling. J Exp Med. 2008;205(10):2339-2347.
53. Zarbock A, Lowell CA, Ley K. Spleen tyrosine kinase Syk is necessary for E-selectin-induced (L)(2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity. 2007;26(6):773-783.
54. Mueller H, et al. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) gamma2 and PI3Kgamma pathways. Blood. 2010;115(15):3118-3127.
55. Stadtmann A, et al. Rap1a activation by CalDAGGEFI and p38 MAPK is involved in E-selectindependent slow leukocyte rolling. Eur J Immunol. 2011;41(7):2074-2085.
56. Stadtmann A, et al. The PSGL-1-L-selectin signaling complex regulates neutrophil adhesion under flow. J Exp Med. 2013;210(11):2171-2180.
57. Germena G, Volmering S, Sohlbach C, Zarbock A. Mutation in the CD45 inhibitory wedge modulates integrin activation and leukocyte recruitment during inflammation. J Immunol. 2015;194(2):728-738.
58. Schnoor M, et al. Cortactin deficiency is associated with reduced neutrophil recruitment but increased vascular permeability in vivo. J Exp Med. 2011;208(8):1721-1735.